CAMBRIDGE, Mass.--(BUSINESS WIRE)--Millennium: The Takeda Oncology Company today reported results from three studies in relapsed multiple myeloma (MM). Two of the studies examined the use of VELCADE® (bortezomib) for Injection; the third study presents clinical data on MLN9708, the first investigational oral proteasome inhibitor.
